Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review focuses on the various skin toxicities caused by chemotherapeutic and targeted tumor therapy drugs, including rashes, keratoacanthoma, and more severe conditions like Stevens-Johnson syndrome, without presenting new clinical results.

This study found that EGFR inhibitors and ligands did not significantly affect the expression of inflammatory biomarkers in cultured sebocytes, except for a notable increase in IL-1 expression with EGF treatment.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

This case report documents new hair growth in a 57-year-old man with androgenic alopecia after receiving gefitinib treatment for non-small-cell lung cancer.

This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

This genetic study identified a potential interval for the Marie Unna hypotrichosis gene but found no mutations in the nearby hr gene, suggesting its involvement remains unconfirmed.

This collection of research news highlights various scientific advancements, including discoveries in anti-cancer compounds, new cell types that boost immunity, and a potential Parkinson's breakthrough in Australia, among others from China, India, Korea, Singapore, and Thailand.

This research reported that docetaxel is generally safe and effective for elderly patients with solid tumor malignancies, showing no significant age-related differences in efficacy or toxicity.

This study suggests that the keratins found in reptile and bird skin appendages evolved independently from mammalian hair keratins, highlighting convergent evolution in these species.

In this study, Gaussian process regression models combined with Grey Wolf optimization were used to predict and optimize phenolic and flavonoid content extraction from Carthamus caeruleus L. rhizomes, showing high accuracy and helping improve understanding and extraction processes through a new interactive tool.

This review discusses the integration of Artificial Intelligence in non-surgical cosmetic procedures, highlighting its potential to improve personalized aesthetic care and operational efficiency while addressing ethical and regulatory challenges; it presents no new clinical findings.

In this laboratory study, α-mangostin was found to significantly reduce melanin content and downregulate pigmentation-related genes in cultured skin and B16F10 cells, suggesting potential application as a natural whitening agent in sunscreen development.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This study reviewed evidence on eribulin's efficacy and safety for treating metastatic triple-negative breast cancer, highlighting variable survival outcomes and manageable safety profiles for both monotherapy and combination therapies.

This study reported that while general patient characteristics and adverse event incidence for eribulin were comparable between a healthcare claims database and post-marketing surveillance, significant differences in some side effects such as neutropenia were observed.

This review discusses evidence from recent clinical trials showing inclisiran effectively lowers LDL cholesterol levels in patients with cardiovascular disease, leading to its use in the UK despite not being approved by the FDA.

Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.

This study observed that Icariside II, an extract from Epimedium brevicornu Maxim, can inhibit the growth of gastric cancer in cell lines and mouse models by promoting apoptosis and suppressing the Wnt/β-catenin signaling pathway, with minimal toxicity to normal gastric cells.

In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

This abstract provides information on various oral contraceptives, their potential hazardous interactions, and possible side effects, without presenting new research findings.

This case report describes a patient who developed PRIDE syndrome-associated skin issues, including a pruritic papulopustular rash and alopecia, after starting treatment with the EGFR inhibitor erlotinib.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.